| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Contrast Media |
1 From the Departments of Radiology (M.R.P., H.E.E., Y.W.), Medicine (J.B.), Pathology (R.W.L.), and Vascular Surgery (K.C.K., H.L.B.), Weill Medical College of Cornell University, 416 E 55th St, New York, NY 10021; and the Rogosin Institute, New York, NY (J.B.). Received December 7, 2001; revision requested February 18, 2002; final revision received January 22, 2003; accepted January 27. Address correspondence to M.R.P. (e-mail: map2008@med.cornell.edu).
PURPOSE: To evaluate the prevalence of spurious hypocalcemia after gadodiamide-enhanced magnetic resonance (MR) imaging.
MATERIALS AND METHODS: Eight hundred ninety-six inpatients with available serum calcium data obtained before and after gadodiamide-enhanced MR imaging were identified. Changes in serum calcium measurements following gadodiamide administration in 1,049 MR imaging examinations performed in these patients were correlated with gadodiamide dose, renal function, and time between gadodiamide administration and phlebotomy.
RESULTS: Following 42 gadodiamide-enhanced examinations, serum calcium measurements spuriously decreased by more than 2 mg/dL (0.5 mmol/L), resulting in laboratory reports of "critical" hypocalcemia (ie, calcium level < 6 mg/dL [1.5 mmol/L]) in 25 examinations. These reduced calcium measurements were correlated with serum creatinine level (r = 0.39, P < .001), gadodiamide dose (r = 0.37, P < .001), and time between gadodiamide injection and phlebotomy (r = -0.28, P < .001). Spurious reductions in calcium measurements after administration of 0.1 mmol of gadodiamide per kilogram of body weight were greater in patients with renal insufficiency (0.6 mg/dL [0.15 mmol/L] ± 0.5 [0.125, SD]) than in those with normal renal function (0.14 mg/dL [0.035 mmol/L] ± 0.4 [0.1]) (P < .001). After administration of more than 0.2 mmol/kg of gadodiamide, spurious calcium measurement decreases were greater in patients with renal insufficiency (2.4 mg/dL [0.6 mmol/L] ± 3.6 [0.9]) than in those with normal renal function (0.4 mg/dL [0.1 mmol/L] ± 0.7 [0.175]) (P < .001). Patients with renal insufficiency had spuriously low calcium measurements up to 4
days after gadodiamide administration. Seven patients were inappropriately treated with intravenous calcium and eleven with oral calcium in response to false-positive laboratory reports of critical hypocalcemia. No patient had characteristic symptoms of hypocalcemia or injuries attributed to the inappropriate medical treatment.
CONCLUSION: Gadodiamide administration causes spurious hypocalcemia, particularly at doses of 0.2 mmol/kg or higher and in patients with renal insufficiency.
© RSNA, 2003
Index terms: Calcium • Contrast media • Contrast media, effects • Magnetic resonance (MR), contrast media, **.121432
Related Article
Radiology 2003 227: 627-628.
This article has been cited by other articles:
|
|
 |
|
  G. C. Kane, A. W. Stanson, D. Kalnicka, D. W. Rosenthal, C. U. Lee, S. C. Textor, and V. D. Garovic Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1233 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Wiginton, B. Kelly, A. Oto, M. Jesse, P. Aristimuno, R. Ernst, and G. Chaljub Gadolinium-Based Contrast Exposure, Nephrogenic Systemic Fibrosis, and Gadolinium Detection in Tissue Am. J. Roentgenol., April 1, 2008; 190(4): 1060 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Gandhi, V. R. Narra, J. J. Brown, A. Guo, D. S. Grosu, C. A. Parvin, and M. G. Scott Clinical and Economic Impact of Falsely Decreased Calcium Values Caused by Gadoversetamide Interference Am. J. Roentgenol., March 1, 2008; 190(3): W213 - W217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Brown, M. R. Hynes, and J. H. Wible Jr. Measurement of Serum Calcium Concentration After Administration of Four Gadolinium-Based Contrast Agents to Human Volunteers Am. J. Roentgenol., December 1, 2007; 189(6): 1539 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Broome, M. S. Girguis, P. W. Baron, A. C. Cottrell, I. Kjellin, and G. A. Kirk Gadodiamide-Associated Nephrogenic Systemic Fibrosis: Why Radiologists Should Be Concerned Am. J. Roentgenol., February 1, 2007; 188(2): 586 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Mark, E. Mazonakis, D. Shapiro, R. J. Spooner, and R. Stuart C. Rodger Pseudohypocalcaemia in an elderly patient with advanced renal failure and renovascular disease Nephrol. Dial. Transplant., July 1, 2005; 20(7): 1499 - 1500. [Full Text] [PDF]
|
|
|
|
|
|
M. Decupere, V. Ooms, R. Oyen, D. R. J. Kuypers, and K. Claes Artifactual hypocalcaemia after intravenous administration of gadodiamide (Omniscan(R)) Nephrol. Dial. Transplant., July 1, 2005; 20(7): 1516 - 1517. [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Wible Jr and M. R. Hynes Measurement of Serum Calcium Concentration after Administration of Gadoversetamide in Dogs Radiology, October 1, 2004; 233(1): 158 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Kang, M. G. Scott, B. N. Joe, V. Narra, J. Heiken, and C. A. Parvin Model for Predicting the Impact of Gadolinium on Plasma Calcium Measured by the o-Cresolphthalein Method Clin. Chem., April 1, 2004; 50(4): 741 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Prince, P. L. Choyke, M. V. Knopp, C. J. Doorenbos, K. Koster, and M. van Wijnen More on Pseudohypocalcemia and Gadolinium-Enhanced MRI N. Engl. J. Med., January 1, 2004; 350(1): 87 - 88. [Full Text] [PDF]
|
|
|
|
|
|
P. L. Choyke and M. V. Knopp Pseudohypocalcemia with MR Imaging Contrast Agents: A Cautionary Tale Radiology, June 1, 2003; 227(3): 627 - 628. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOLOGY | RADIOGRAPHICS | RSNA JOURNALS ONLINE |
